Designed for experts in academia and industry working in this exciting field, this conference will examine cutting-edge
research in several key areas across four dedicated tracks. Talks will look to cover the development of scaffold
technology for both soft and hard tissues, and the novel biomaterials used in their construction, new platforms for
Biofabrication, tissue culture techniques, advances in hydrogels in regenerative medicine, and recent developments in
stem cell research. There will also be a track dedicated to the exciting developing field of organ fabrication, reviewing
recent advances and challenges to be overcome.
Embryogenic evolution emulates in silico cell-like entities to get more powerful methods for complex evolutionary tasks. As simulations have to abstract from the biological model, implicit information hidden in its physics is lost. Here, we propose to use cell-like entities as a real-world in vitro testbed. In analogy to evolutionary robotics, where solutions evolved in simulations may be tested in real-world on macroscale, the proposed vesicular testbed would do the same for the embryogenic evolutionary tasks on mesoscale. As a first step towards a vesicular testbed emulating growth, cell division, and cell differentiation, we present a modified vesicle production method, providing custom tailored chemical cargo, and present a novel self-assembly procedure to provide vesicle aggregates of programmable composition.
Vesicular Testbeds for Embryogenic Evolutionary Systems – How to Connect Wet and Soft Artificial Life. The Fourth Australian Conference on Artificial Life (ACAL09), Melbourne, Australia (1-4 December 2009), 20 minutes oral presentation.
Embryogenic evolution emulates in silico cell-like entities to get more powerful methods for complex evolutionary tasks. As simulations have to abstract from the biological model, implicit information hidden in its physics is lost. Here, we propose to use cell-like entities as a real-world in vitro testbed. In analogy to evolutionary robotics, where solutions evolved in simulations may be tested in real-world on macroscale, the proposed vesicular testbed would do the same for the embryogenic evolutionary tasks on mesoscale. As a first step towards a vesicular testbed emulating growth, cell division, and cell differentiation, we present a modified vesicle production method, providing custom tailored chemical cargo, and present a novel self-assembly procedure to provide vesicle aggregates of programmable composition.
Vesicular Testbeds for Embryogenic Evolutionary Systems – How to Connect Wet and Soft Artificial Life. The Fourth Australian Conference on Artificial Life (ACAL09), Melbourne, Australia (1-4 December 2009), 20 minutes oral presentation.
Nano-Biomaterials and Their Biocompatibility in Restorative Dentistry: A Reviewinventionjournals
Human healthcare is facing a major uprising in the wake of ongoing technological expansions in the field of nanotechnology. Incorporation of nanotechnology into dentistry will make possible the maintenance of near perfect oral environment by using nanomaterials, including tissue engineering, and ultimately, dental nanorobots. New potential treatment prospects in dentistry may include: dentition renaturalization and permanent hypersensitivity cure, local anaesthesia, complete orthodontic realignments during a single office visit, covalently bonded diamondised enamel, and oral health maintenance using mechanical dentifrobots, to destroy bacteria in the mouth that cause dental caries or even repair spots on the teeth where decay has set in, by use of computer to direct these tiny workers in their tasks. Nanodentistry still faces many significant challenges in realizing its tremendous potential. There are larger social issues of public acceptance, regulations, ethics and human safety that must be taken into consideration before molecular nano-technology can enter the modern medical armamentarium. However, there is equally powerful motivation to surmount these various challenges such as the possibility of providing high quality dental care to 80% of the population that at present receives no noteworthy dental care. Time, financial and scientific resources, specific advances and human needs will conclude which of the applications to be realized first!
170411 nanomedicine new strategies in targeted delivery (daniela wilson), inn...SMBBV
Publication of presentation by dr. Daniela Wilson, theme leader Nanomedicine at Radboud University Science Faculty on New strategies in targeted delivery. Innoboot 2017, Nijmegen, The Netherlands on April 11, 2017.
Living Technology is researching novel IT making strong use of programmable chemical systems. These chemical systems shall finally converge to artificial cells resulting in evolvable complex information systems. We focus on procedural manageability and information processing capabilities of such information systems. Here, we present a novel resource-saving formation, processing, and examination procedure to generate and handle single compartments representing preliminary stages of artificial cells. Its potential is exemplified by testing the influence of different glycerophospholipids on the stability of the compartments. We discuss how the procedure could be used both in evolutionary optimization of self-assembling amphiphilic systems and in engineering tailored communication networks enabling life-like information processing in multicompartment aggregates of programmable composition and spatial configuration.
MultiCompartment Communication Networks (MCCNs) – Entities of Wet Artificial Life. The Fourth Australian Conference on Artificial Life (ACAL09), Melbourne, Australia (1-4 December 2009), 20 minutes oral presentation.
Curso sobre biofabricação de tecidos do Núcleo de Tecnologias Tridimensionais (NT3D) do Centro de Tecnologia da Informação Renato Archer. Os assuntos abordados incluem os seguintes tópicos:
•Conceitos da bioimpressão e biofabricação de tecidos;
•Engenharia tecidual;
•Tecnologias envolvidas;
•O papel da tecnologia da informação na bioimpressão de tecidos;
•Projetos desenvolvidos no Brasil e no mundo sobre bioimpressão de tecidos.
It has been almost decades since the “war on cancer” was declared. It is now generally
believed that personalized medicine is the future for cancer patient management.
Possessing unprecedented potential for early detection, accurate diagnosis, and
personalized treatment of cancer, nanoparticles have been extensively studied over the last
decade. In this report, I will try to summarize the current state-of-the-art nanoparticles in
biomedical applications targeting cancer. Multi- functionality nanoparticle-based agents.
Targeting ligands, imaging labels, therapeutic Drugs, and other. And the Role of Chemical
Engineers in this field and the promise that it holds for future.
This was an introductory talk I gave at Ben Gurion University of the Negev in Israel on the 23rd/June/2009. These are a series of talks for the period in which I visited BGU as a distinguished visiting scientist.
Nano-Biomaterials and Their Biocompatibility in Restorative Dentistry: A Reviewinventionjournals
Human healthcare is facing a major uprising in the wake of ongoing technological expansions in the field of nanotechnology. Incorporation of nanotechnology into dentistry will make possible the maintenance of near perfect oral environment by using nanomaterials, including tissue engineering, and ultimately, dental nanorobots. New potential treatment prospects in dentistry may include: dentition renaturalization and permanent hypersensitivity cure, local anaesthesia, complete orthodontic realignments during a single office visit, covalently bonded diamondised enamel, and oral health maintenance using mechanical dentifrobots, to destroy bacteria in the mouth that cause dental caries or even repair spots on the teeth where decay has set in, by use of computer to direct these tiny workers in their tasks. Nanodentistry still faces many significant challenges in realizing its tremendous potential. There are larger social issues of public acceptance, regulations, ethics and human safety that must be taken into consideration before molecular nano-technology can enter the modern medical armamentarium. However, there is equally powerful motivation to surmount these various challenges such as the possibility of providing high quality dental care to 80% of the population that at present receives no noteworthy dental care. Time, financial and scientific resources, specific advances and human needs will conclude which of the applications to be realized first!
170411 nanomedicine new strategies in targeted delivery (daniela wilson), inn...SMBBV
Publication of presentation by dr. Daniela Wilson, theme leader Nanomedicine at Radboud University Science Faculty on New strategies in targeted delivery. Innoboot 2017, Nijmegen, The Netherlands on April 11, 2017.
Living Technology is researching novel IT making strong use of programmable chemical systems. These chemical systems shall finally converge to artificial cells resulting in evolvable complex information systems. We focus on procedural manageability and information processing capabilities of such information systems. Here, we present a novel resource-saving formation, processing, and examination procedure to generate and handle single compartments representing preliminary stages of artificial cells. Its potential is exemplified by testing the influence of different glycerophospholipids on the stability of the compartments. We discuss how the procedure could be used both in evolutionary optimization of self-assembling amphiphilic systems and in engineering tailored communication networks enabling life-like information processing in multicompartment aggregates of programmable composition and spatial configuration.
MultiCompartment Communication Networks (MCCNs) – Entities of Wet Artificial Life. The Fourth Australian Conference on Artificial Life (ACAL09), Melbourne, Australia (1-4 December 2009), 20 minutes oral presentation.
Curso sobre biofabricação de tecidos do Núcleo de Tecnologias Tridimensionais (NT3D) do Centro de Tecnologia da Informação Renato Archer. Os assuntos abordados incluem os seguintes tópicos:
•Conceitos da bioimpressão e biofabricação de tecidos;
•Engenharia tecidual;
•Tecnologias envolvidas;
•O papel da tecnologia da informação na bioimpressão de tecidos;
•Projetos desenvolvidos no Brasil e no mundo sobre bioimpressão de tecidos.
It has been almost decades since the “war on cancer” was declared. It is now generally
believed that personalized medicine is the future for cancer patient management.
Possessing unprecedented potential for early detection, accurate diagnosis, and
personalized treatment of cancer, nanoparticles have been extensively studied over the last
decade. In this report, I will try to summarize the current state-of-the-art nanoparticles in
biomedical applications targeting cancer. Multi- functionality nanoparticle-based agents.
Targeting ligands, imaging labels, therapeutic Drugs, and other. And the Role of Chemical
Engineers in this field and the promise that it holds for future.
This was an introductory talk I gave at Ben Gurion University of the Negev in Israel on the 23rd/June/2009. These are a series of talks for the period in which I visited BGU as a distinguished visiting scientist.
Univ of IL Micro + Nanotechnology Lab highlightsLaura Schmitt
The latest advances from one of the premier university-based photonics, microelectronics, biotechnology, and nanotechnology research facilities in the country.
Dr. Hugh C. DeLong presents an overview of his program, Natural Materials and Systems, at the AFOSR 2013 Spring Review. At this review, Program Officers from AFOSR Technical Divisions will present briefings that highlight basic research programs beneficial to the Air Force.
Join us in Boston this coming Fall to attend Cambridge Healthtech Institute's (CHI) 2nd Annual FAST: Functional Analysis & Screening Technologies Congress on November 17-19, 2014 and meet with a community of 250+ biologists, screening managers, assay developers, engineers and pharmacologists dedicated to improving in vitro cell models and phenotypic screening to advance drug discovery and development at 6 conferences: Phenotypic Drug Discovery (Part I & II), Engineering Functional 3D Models, Screening and Functional Analysis of 3D Models, Organotypic Culture Models for Toxicology and Physiologically-Relevant Cellular Tumor Models for Drug Discovery. Delegates have the opportunity to share insights in interactive panel discussions and connect during networking breaks. View innovative technologies and scientific research revolutionizing early-stage drug discovery in the exhibit/poster hall.
Similar to Biomaterials & Tissue engineering - London - Agenda (20)
Precision Medicine & Biomarkers Leaders Summit - Boston USA - 7th & 8th MayTony Couch
This expanding series attracts the leading authorities worldwide working in companion diagnostics, biomarkers, immuno-oncology, liquid biopsies, AI and other facets of precision medicine. It has been praised for its stimulating, interactive and engaging environment where it brings together a multi-disciplined community of researchers, leaders and innovators whose aim is to develop groundbreaking and impactful treatments for patients.
Precision Medicine & Biomarkers Leaders Summit - Boston USA - 7th & 8th MayTony Couch
Tracks focus on R&D strategies, Biomarker development, Immuno-oncology, CDx development, AI and Big data analysis and approaches – Attending this Summit will provide you with the opportunity to mix and interact with experts working in all facets of Precision Medicine through the individual, panel and roundtable discussions on offer.
Precision Medicine & Biomarkers Leaders Summit - Boston USA - 7th & 8th MayTony Couch
Global Engage is pleased to announce the 2018 Precision Medicine & Biomarkers Leaders Summit USA taking place on May 7-8th in Boston, MA. The event is part of our highly successful Drug Discovery Series which includes conferences on Biologics, Medicinal Chemistry, NASH, Pharmaceutical R&D IT and the Human Microbiome amongst others. It is also the sister meeting of the European Precision Medicine Summit which has run successfully since 2013.
The conference will provide an interactive networking forum to both further develop and answer your queries through a vibrant exhibition room full of technology providers showcasing their technologies and other solutions, poster presentation sessions, expert led case study presentations, a high-level panel discussion, a round table discussion session, and interactive Q&A sessions from a 40-strong speaker faculty examining topics on 4 separate tracks outlined below.
Designed to attract experts working in all areas of medicinal chemistry and molecular pharmacology the summit has five tracks focusing on key issues such as optimising hit to lead quality and timescale, protein degradation, DNA Encoded libraries, GPCR’s, small molecule Immuno-oncology research, FBDD, SBDD, CADD as well as best strategies for partnerships, collaborations, outsourcing and integration of research. The Summit will provide a forum to network, learn and engage with senior representatives of leading pharmaceutical and biotech companies worldwide. It is a gathering not to be missed!
Designed to attract experts working in all areas of medicinal chemistry and molecular pharmacology the summit has five tracks focusing on key issues such as optimising hit to lead quality and timescale, protein degradation, DNA Encoded libraries, GPCR’s, small molecule Immuno-oncology research, FBDD, SBDD, CADD as well as best strategies for partnerships, collaborations, outsourcing and integration of research. The Summit will provide a forum to network, learn and engage with senior representatives of leading pharmaceutical and biotech companies worldwide. It is a gathering not to be missed!
After the success of the previous edition - Bioprocessing of Advanced Cellular Therapies Congress 2016, MarketsandMarkets is pleased to announce the 2nd Annual Bioprocessing of Advanced Cellular Therapies Congress in London, UK.
Research Organizations and Pharma companies have been investing big time into the promise of cellular therapies and all signs point to the need to accelerate the process of moving from lab to patient using advanced manufacturing processes and solutions to commercialization.
With this objective, making the shift from manual processes to automation, bridging the gap between research lab and market place, and using novel and advanced technologies will be the key aspects for manufacturers to answer the challenge of scale-out.
The 2nd Annual Bioprocessing of Advanced Cellular Therapies Congress taking place on the 8th and 9th June, 2017 in London, UK focuses on this holistic approach by discussing the next generation bioprocessing, strategies, technologies and solutions to work together for this constantly evolving field.
2nd Annual Infection Control, Sterilization and Decontamination in Healthcare...Tony Couch
After the success of inaugural congress held on 25th-26th February 2016, MnM Conferences is organizing 2nd Annual Infection Control, Sterilization and Decontamination in Healthcare Congress, scheduled for 21st & 22nd March 2017 in London, UK aiming at providing platform to experts from hospitals, academia, and government institutions discussing the innovations, challenges, and future aspects of infection control, decontamination, and sterilization.
2nd Epigenetics Discovery congress - Latest agendaTony Couch
Advancements in Epigenetics have certainly given us huge breakthroughs in drug discovery, development and effective diagnosis of diseases. Scientists are working towards making new developments and address challenges in epigenetics for cancer, neurodegenerative diseases and other ailments. The Epigenetics Discovery Congress will provide a platform to such scientists to present their work, learn what their peers are doing, share experiences and overcome challenges that the industry is facing.....
Bioprocessing of Advanced Cellular Therapies CongressTony Couch
Last opportunity to get onto the programme.
Key sessions:
• Upstream process development for gene therapies
• Upstream process development for cell based therapies
• Downstream processing considerations
• Analytics - tackling measurement assurance for advanced cellular therapeutics
• Insights into Business Development and Reimbursement
• Regulatory perspectives
Richard's entangled aventures in wonderlandRichard Gill
Since the loophole-free Bell experiments of 2020 and the Nobel prizes in physics of 2022, critics of Bell's work have retreated to the fortress of super-determinism. Now, super-determinism is a derogatory word - it just means "determinism". Palmer, Hance and Hossenfelder argue that quantum mechanics and determinism are not incompatible, using a sophisticated mathematical construction based on a subtle thinning of allowed states and measurements in quantum mechanics, such that what is left appears to make Bell's argument fail, without altering the empirical predictions of quantum mechanics. I think however that it is a smoke screen, and the slogan "lost in math" comes to my mind. I will discuss some other recent disproofs of Bell's theorem using the language of causality based on causal graphs. Causal thinking is also central to law and justice. I will mention surprising connections to my work on serial killer nurse cases, in particular the Dutch case of Lucia de Berk and the current UK case of Lucy Letby.
Richard's aventures in two entangled wonderlandsRichard Gill
Since the loophole-free Bell experiments of 2020 and the Nobel prizes in physics of 2022, critics of Bell's work have retreated to the fortress of super-determinism. Now, super-determinism is a derogatory word - it just means "determinism". Palmer, Hance and Hossenfelder argue that quantum mechanics and determinism are not incompatible, using a sophisticated mathematical construction based on a subtle thinning of allowed states and measurements in quantum mechanics, such that what is left appears to make Bell's argument fail, without altering the empirical predictions of quantum mechanics. I think however that it is a smoke screen, and the slogan "lost in math" comes to my mind. I will discuss some other recent disproofs of Bell's theorem using the language of causality based on causal graphs. Causal thinking is also central to law and justice. I will mention surprising connections to my work on serial killer nurse cases, in particular the Dutch case of Lucia de Berk and the current UK case of Lucy Letby.
Introduction:
RNA interference (RNAi) or Post-Transcriptional Gene Silencing (PTGS) is an important biological process for modulating eukaryotic gene expression.
It is highly conserved process of posttranscriptional gene silencing by which double stranded RNA (dsRNA) causes sequence-specific degradation of mRNA sequences.
dsRNA-induced gene silencing (RNAi) is reported in a wide range of eukaryotes ranging from worms, insects, mammals and plants.
This process mediates resistance to both endogenous parasitic and exogenous pathogenic nucleic acids, and regulates the expression of protein-coding genes.
What are small ncRNAs?
micro RNA (miRNA)
short interfering RNA (siRNA)
Properties of small non-coding RNA:
Involved in silencing mRNA transcripts.
Called “small” because they are usually only about 21-24 nucleotides long.
Synthesized by first cutting up longer precursor sequences (like the 61nt one that Lee discovered).
Silence an mRNA by base pairing with some sequence on the mRNA.
Discovery of siRNA?
The first small RNA:
In 1993 Rosalind Lee (Victor Ambros lab) was studying a non- coding gene in C. elegans, lin-4, that was involved in silencing of another gene, lin-14, at the appropriate time in the
development of the worm C. elegans.
Two small transcripts of lin-4 (22nt and 61nt) were found to be complementary to a sequence in the 3' UTR of lin-14.
Because lin-4 encoded no protein, she deduced that it must be these transcripts that are causing the silencing by RNA-RNA interactions.
Types of RNAi ( non coding RNA)
MiRNA
Length (23-25 nt)
Trans acting
Binds with target MRNA in mismatch
Translation inhibition
Si RNA
Length 21 nt.
Cis acting
Bind with target Mrna in perfect complementary sequence
Piwi-RNA
Length ; 25 to 36 nt.
Expressed in Germ Cells
Regulates trnasposomes activity
MECHANISM OF RNAI:
First the double-stranded RNA teams up with a protein complex named Dicer, which cuts the long RNA into short pieces.
Then another protein complex called RISC (RNA-induced silencing complex) discards one of the two RNA strands.
The RISC-docked, single-stranded RNA then pairs with the homologous mRNA and destroys it.
THE RISC COMPLEX:
RISC is large(>500kD) RNA multi- protein Binding complex which triggers MRNA degradation in response to MRNA
Unwinding of double stranded Si RNA by ATP independent Helicase
Active component of RISC is Ago proteins( ENDONUCLEASE) which cleave target MRNA.
DICER: endonuclease (RNase Family III)
Argonaute: Central Component of the RNA-Induced Silencing Complex (RISC)
One strand of the dsRNA produced by Dicer is retained in the RISC complex in association with Argonaute
ARGONAUTE PROTEIN :
1.PAZ(PIWI/Argonaute/ Zwille)- Recognition of target MRNA
2.PIWI (p-element induced wimpy Testis)- breaks Phosphodiester bond of mRNA.)RNAse H activity.
MiRNA:
The Double-stranded RNAs are naturally produced in eukaryotic cells during development, and they have a key role in regulating gene expression .
Seminar of U.V. Spectroscopy by SAMIR PANDASAMIR PANDA
Spectroscopy is a branch of science dealing the study of interaction of electromagnetic radiation with matter.
Ultraviolet-visible spectroscopy refers to absorption spectroscopy or reflect spectroscopy in the UV-VIS spectral region.
Ultraviolet-visible spectroscopy is an analytical method that can measure the amount of light received by the analyte.
(May 29th, 2024) Advancements in Intravital Microscopy- Insights for Preclini...Scintica Instrumentation
Intravital microscopy (IVM) is a powerful tool utilized to study cellular behavior over time and space in vivo. Much of our understanding of cell biology has been accomplished using various in vitro and ex vivo methods; however, these studies do not necessarily reflect the natural dynamics of biological processes. Unlike traditional cell culture or fixed tissue imaging, IVM allows for the ultra-fast high-resolution imaging of cellular processes over time and space and were studied in its natural environment. Real-time visualization of biological processes in the context of an intact organism helps maintain physiological relevance and provide insights into the progression of disease, response to treatments or developmental processes.
In this webinar we give an overview of advanced applications of the IVM system in preclinical research. IVIM technology is a provider of all-in-one intravital microscopy systems and solutions optimized for in vivo imaging of live animal models at sub-micron resolution. The system’s unique features and user-friendly software enables researchers to probe fast dynamic biological processes such as immune cell tracking, cell-cell interaction as well as vascularization and tumor metastasis with exceptional detail. This webinar will also give an overview of IVM being utilized in drug development, offering a view into the intricate interaction between drugs/nanoparticles and tissues in vivo and allows for the evaluation of therapeutic intervention in a variety of tissues and organs. This interdisciplinary collaboration continues to drive the advancements of novel therapeutic strategies.
Observation of Io’s Resurfacing via Plume Deposition Using Ground-based Adapt...Sérgio Sacani
Since volcanic activity was first discovered on Io from Voyager images in 1979, changes
on Io’s surface have been monitored from both spacecraft and ground-based telescopes.
Here, we present the highest spatial resolution images of Io ever obtained from a groundbased telescope. These images, acquired by the SHARK-VIS instrument on the Large
Binocular Telescope, show evidence of a major resurfacing event on Io’s trailing hemisphere. When compared to the most recent spacecraft images, the SHARK-VIS images
show that a plume deposit from a powerful eruption at Pillan Patera has covered part
of the long-lived Pele plume deposit. Although this type of resurfacing event may be common on Io, few have been detected due to the rarity of spacecraft visits and the previously low spatial resolution available from Earth-based telescopes. The SHARK-VIS instrument ushers in a new era of high resolution imaging of Io’s surface using adaptive
optics at visible wavelengths.
Multi-source connectivity as the driver of solar wind variability in the heli...Sérgio Sacani
The ambient solar wind that flls the heliosphere originates from multiple
sources in the solar corona and is highly structured. It is often described
as high-speed, relatively homogeneous, plasma streams from coronal
holes and slow-speed, highly variable, streams whose source regions are
under debate. A key goal of ESA/NASA’s Solar Orbiter mission is to identify
solar wind sources and understand what drives the complexity seen in the
heliosphere. By combining magnetic feld modelling and spectroscopic
techniques with high-resolution observations and measurements, we show
that the solar wind variability detected in situ by Solar Orbiter in March
2022 is driven by spatio-temporal changes in the magnetic connectivity to
multiple sources in the solar atmosphere. The magnetic feld footpoints
connected to the spacecraft moved from the boundaries of a coronal hole
to one active region (12961) and then across to another region (12957). This
is refected in the in situ measurements, which show the transition from fast
to highly Alfvénic then to slow solar wind that is disrupted by the arrival of
a coronal mass ejection. Our results describe solar wind variability at 0.5 au
but are applicable to near-Earth observatories.
Cancer cell metabolism: special Reference to Lactate PathwayAADYARAJPANDEY1
Normal Cell Metabolism:
Cellular respiration describes the series of steps that cells use to break down sugar and other chemicals to get the energy we need to function.
Energy is stored in the bonds of glucose and when glucose is broken down, much of that energy is released.
Cell utilize energy in the form of ATP.
The first step of respiration is called glycolysis. In a series of steps, glycolysis breaks glucose into two smaller molecules - a chemical called pyruvate. A small amount of ATP is formed during this process.
Most healthy cells continue the breakdown in a second process, called the Kreb's cycle. The Kreb's cycle allows cells to “burn” the pyruvates made in glycolysis to get more ATP.
The last step in the breakdown of glucose is called oxidative phosphorylation (Ox-Phos).
It takes place in specialized cell structures called mitochondria. This process produces a large amount of ATP. Importantly, cells need oxygen to complete oxidative phosphorylation.
If a cell completes only glycolysis, only 2 molecules of ATP are made per glucose. However, if the cell completes the entire respiration process (glycolysis - Kreb's - oxidative phosphorylation), about 36 molecules of ATP are created, giving it much more energy to use.
IN CANCER CELL:
Unlike healthy cells that "burn" the entire molecule of sugar to capture a large amount of energy as ATP, cancer cells are wasteful.
Cancer cells only partially break down sugar molecules. They overuse the first step of respiration, glycolysis. They frequently do not complete the second step, oxidative phosphorylation.
This results in only 2 molecules of ATP per each glucose molecule instead of the 36 or so ATPs healthy cells gain. As a result, cancer cells need to use a lot more sugar molecules to get enough energy to survive.
Unlike healthy cells that "burn" the entire molecule of sugar to capture a large amount of energy as ATP, cancer cells are wasteful.
Cancer cells only partially break down sugar molecules. They overuse the first step of respiration, glycolysis. They frequently do not complete the second step, oxidative phosphorylation.
This results in only 2 molecules of ATP per each glucose molecule instead of the 36 or so ATPs healthy cells gain. As a result, cancer cells need to use a lot more sugar molecules to get enough energy to survive.
introduction to WARBERG PHENOMENA:
WARBURG EFFECT Usually, cancer cells are highly glycolytic (glucose addiction) and take up more glucose than do normal cells from outside.
Otto Heinrich Warburg (; 8 October 1883 – 1 August 1970) In 1931 was awarded the Nobel Prize in Physiology for his "discovery of the nature and mode of action of the respiratory enzyme.
WARNBURG EFFECT : cancer cells under aerobic (well-oxygenated) conditions to metabolize glucose to lactate (aerobic glycolysis) is known as the Warburg effect. Warburg made the observation that tumor slices consume glucose and secrete lactate at a higher rate than normal tissues.
This pdf is about the Schizophrenia.
For more details visit on YouTube; @SELF-EXPLANATORY;
https://www.youtube.com/channel/UCAiarMZDNhe1A3Rnpr_WkzA/videos
Thanks...!
Biomaterials & Tissue engineering - London - Agenda
1. EXAMINING THE LATEST SCIENTIFIC ADVANCES IN BIOMATERIAL RESEARCH, PLATFORM
TECHNOLOGIES AND APPROACHES TO HARD AND SOFT TISSUE ENGINEERING
Conference Synopsis
Day 1 Track 1
Soft Tissue Engineering & Regenerative Medicine
• Advances in tissue culturing techniques
• Development of novel scaffolds for soft tissues
• Success case studies in regenerative medicine for nerve and cardiac tissue reconstruction
• Reviewing methods of stem cells generation and differentiation (internal and external stimuli)
• Nuclear reprogramming and gene editing approaches (CRISPR-Cas 9 applications)
Day 1 Track 2
Biomaterials & Bio Fabrication – Platforms & Technologies
• Advances in materials for scaffolds
• Polymer technology – current and future developments
• Optimising injectable scaffolds
• Challenges in developing nanomaterial & nanofiber technology
• 3D bio-printing techniques
• CAD/CAM techniques
Day 2 Track 1
Hard Tissue & Cartilage Engineering
• Exploring factors in bone degeneration and advances in regeneration techniques
• The role of hydrogels in hard tissue engineering
• Biomaterials (polymer, fibre and beyond)
• Beyond bone: reviewing progress in tissue engineering approaches to cartilage, and regenerative medicine
approaches for arthritis
Day 2 Track 2
Organ Fabrication & Bioprinting
• Artificial organ and organ-mimicking tissue development
• Overcoming the unique problems of scaffold construction for organ fabrication
• Reviewing methods of cell seeding: transplantation, bio-printing, bioreactor immersion
Global Engage is pleased to announce the Biomaterials & Tissue Engineering Conference, taking place on 12th-13th
November 2018, in London, UK.
Designed for experts in academia and industry working in this exciting field, this conference will examine cutting-edge
research in several key areas across four dedicated tracks. Talks will look to cover the development of scaffold
technology for both soft and hard tissues, and the novel biomaterials used in their construction, new platforms for
Biofabrication, tissue culture techniques, advances in hydrogels in regenerative medicine, and recent developments in
stem cell research. There will also be a track dedicated to the exciting developing field of organ fabrication, reviewing
recent advances and challenges to be overcome.
With over 30 individual presentations and 150 expected attendees, this interactive meeting will allow you to keep up to
date with the cutting edge of research and provides the opportunity to make connections with academics, investors,
and businesses in your field.
2. Confirmed Speakers
• Stephen Badylak, Deputy Director of the McGowan Institute for Regenerative Medicine,
University of Pittsburgh
• Gabor Forgacs, George H. Vineyard Professor, University of Missouri
• Marcy Zenobi-Wong, Professor, ETH Zurich
• Jeroen Rouwkema, Associate Professor, University of Twente
• Christine Le Maitre, Professor, Sheffield Hallam University
• Michael McAlpine, Associate Professor of Mechanical Engineering, University of Minnesota
• Frederik Claeyssens, Senior Lecturer in Biomaterials, University of Sheffield
• Carlijn Bouten, Professor and Chair of Cell Matrix Interaction in Cardiovascular Regeneration,
Eindhoven University of Technology
• Sian Harding, Professor & Interim Head of the National Heart & Lung Institute, Imperial College
London
• Julian Dye, Departmental Lecturer, University of Oxford
• Anne des Rieux, Professor, UC Louvain
• Nick Evans, Associate Professor, University of Southampton
• Paul Hatton, Professor, University of Sheffield
• Kevin Shakesheff, Professor of Advanced Drug Delivery and Tissue Engineering, University of
Nottingham
• Kurt Hankenson, Professor, Orthopaedic Surgery, University of Michigan
• Athina Markaki, University Reader, University of Cambridge
• Monica Boffito, Assistant Professor, Politechnico di Torino
• Morgan Alexander, Professor of Biomedical Surfaces, University of Nottingham
• Suwan Jayasinghe, Professor of Mechanical Engineering, UCL
• Hans Van Oosterwyck, Full Professor, KU Leuven
• Pedro Miguel Baptista, Assistant Professor, Universidad Carlos III de Madrid
• Yan Yan "Shery" Huang, Lecturer in Bioengineering, University of Cambridge
• Shirley Tang, Associate Professor, University of Waterloo
• Núria Montserrat Pulido, Junior Group Leader, Institute for Bioengineering of Catalonia
• Joaquin Cortiella, Professor, University of Texas Medical Branch at Galveston
• Helen Berry, University Academic Fellow, University of Leeds
Reserved Speakers
• Aaron James, Associate Professor, John Hopkins University
• Cathy Ye, Associate Professor, University of Oxford
• Mathis Riehl, Reader University of Glasgow
• Debby Gawlitta, Associate Professor, UMC Utrecht
• Oran Kennedy, Royal College of Surgeons in Ireland
• Suchitra Sumitran-Holgersson, Professor of Transplantation, University of Gothenburg
3. 08.00-08.55 Registration & Coffee
08.55-09.00 Global Engage Welcome Address
Track Chair’s Opening Remarks
09.00-09.40 Keynote Presentation
Regenerative Medicine Strategies for Soft Tissue: Lessons from Mother Nature
Confirmed
Stephen Badylak, Deputy Director of the McGowan Institute for Regenerative Medicine, University of Pittsburgh
09.40-10.15 Keynote Presentation
Bioprinting: State of the art
Confirmed
Gabor Forgacs, Professor, University of Missouri
10.15-10.45 Solution Provider Presentation
For sponsorship opportunities please contact
Nick Best/Tony Couch at
Sponsorship@globalengage.co.uk
10.45-11.55 Morning Refreshments
Poster Presentation Sessions
One to One Partnering Meetings
Track 1 – Soft Tissue Engineering & Regenerative Medicine Track 2 – Biomaterials & Biofabrication – Platforms & Technologies
11.55-12.20 Spinal cord injury: how dental stem cells take up the challenge?
Stem cells from the apical papilla (SCAP) derive from the neural crest and express
numerous neurogenic markers. The goal of the present work was to investigate their
therapeutic potential regarding the treatment of spinal cord injury (SCI). We evaluated
the impact of hydrogel properties on SCAP and we selected a fibrin hydrogel as the most
suitable delivery system to evaluate the influence of SCAP for spinal cord regeneration.
Then, we observed that implantation of a whole human apical papilla at the lesion site
improved gait of spinally injured rats. Finally, we demonstrated that SCAP have
immunomodulatory properties and can stimulate oligodendrocyte progenitor cell
differentiation. This work underlines the potential therapeutic benefits of SCAP for spinal
cord repair.
Confirmed
Anne des Rieux, Professor, FNRS Research Associate, UC Louvain
3D Printing Functional Materials & Devices
The ability to three-dimensionally interweave biological and functional materials could
enable the creation of devices possessing unique geometries, properties, and
functionalities. Biology is three-dimensional, often soft and stretchable, and temperature
sensitive. This renders most biological platforms incompatible with the fabrication and
materials processing methods that have been developed and optimized for functional
electronics, which are typically planar, rigid and brittle. Our approach is to use extrusion-
based multi-material 3D printing, which is an additive manufacturing technology that
offers freeform, autonomous fabrication. This approach addresses the dichotomies
presented above by: (1) using 3D printing and imaging for personalized, multifunctional
device architectures; (2) employing ‘nano-inks’ as an enabling route for introducing
diverse material functionality; and (3) 3D printing a range of functional inks to enable the
interweaving of a diverse palette of materials, from biological to electronic. This blending
of 3D printing, functional materials, and ‘living’ platforms may enable next-generation 3D
printed devices.
Confirmed
Michael McAlpine, Associate Professor, University of Minnesota
12.20-12.45 Topic: developing new bioreactors to regenerate nerve tissue
Reserved
Cathy Ye, Associate Professor, University of Oxford
Light-based Additive Manufacturing for tissue engineering
This talk will highlight my group’s work in in laser-based additive manufacturing
techniques and specifically stereolithography to produce 3D structured biomaterials. In
this process we use a UV light source to photocure a light sensitive resin in a spatially
controlled manner to build up a 3D object. We produce biodegradable scaffolds with this
techniques based on polycaprolactone, poly-lactic acid and poly-glycerol sebacate to be
used as implants. Additionally, we use non-degradable materials for building 3D
microenvironments for lab-on-a-chip devices with this technology. Recently, we have
developed the expertise to combine stereolithography with emulsion templating, this
enables additive manufacturing of inherently porous matrices. This opens the route to
Day One – 12th November, London, U.K.
4. hierarchical structured materials, where the structure can be independently controlled
from nanometre to macroscopic length scales. We have used these scaffold materials for
a number of different applications: (i) corneal tissue engineering, (ii) nerve guidance
conduits and (iii) scaffolds for bone-on-a-chip devices.
Confirmed
Frederik Claeyssens, Senior Lecturer, University of Sheffield
12.45-13.15 Solution Provider Presentation
For sponsorship opportunities please contact
Nick Best/Tony Couch at
Sponsorship@globalengage.co.uk
Solution Provider Presentation
For sponsorship opportunities please contact
Nick Best/Tony Couch at
Sponsorship@globalengage.co.uk
13.15-14.15 Lunch
Poster Presentation Sessions
One to One Partnering Meetings
14.15-14.40 Engineering vascularized tissues
Engineered tissues offer a great promise as an alternative for donor tissues, for which
the supply is not meeting the demands. However, currently the clinical application of
engineered tissues is hampered. The integration of engineered tissues after implantation
is limited due to the lack of a vascular network.
Adding a vascular network to an engineered tissue, is a promising method to enhance
integration after implantation. However, in order to integrate and function properly, the
organization of the network is important. Vascular networks in engineered tissues can be
patterned using biofabrication techniques, but these structures will often not be stable
due to tissue remodeling. Therefore a combination with controllable cues that direct
vascular remodeling, is paramount to achieve a controllable long-term organization.
Confirmed
Jeroen Rouwkema, Associate Professor, University of Twente
Injectable and microporous matrices for cell and drug delivery
Precise delivery and retention of cells and drugs at the site of regeneration is essential to
maximise the effectiveness and safety of the therapy. Off-the-shelf injectable matrices
have largely been borrowed from pharmaceutical applications in which the matric does
not need to host angiogenesis and tissue formation. We have developed a new class of
biodegradable materials that form a macroporous scaffolds within the body and nurture
cells to form tissue at the correct location.
Confirmed
Kevin Shakesheff, Professor of Drug Discovery and Tissue Engineering,
University of Nottingham
14.40-15.05 In situ heart valve tissue engineering using slow-degrading elastomeric scaffolds
We investigate and design in situ heart valve tissue engineering technologies using
instructive, cell-free, biodegradable scaffolds as an approach to create living valves
inside the human heart. This lecture addresses the challenges to develop scaffolds that
i) function upon implantation and with time of tissue formation and scaffold degradation,
ii) are capable of harnessing the natural host response, and iii) provide the necessary
cues for a stable and organized load-bearing extracellular matrix in vivo. I will address
how biomimetic in vitro models and computational analyses are used in direct
comparison with in vivo small-animal experiments (orthotopic aorta implantations) to
optimize scaffold biochemical, biophysical, and degradation properties. The resulting
scaffold demonstrates sustained mechanical and biological functionality during long-term
orthotopic (12 month FU) and transcatheter (6 month FU) implantations as pulmonary
valve in sheep. These results offer new perspectives for endogenous heart valve
replacement starting from readily-available synthetic grafts.
Confirmed
Carlijn Bouten, Professor of Cell-Matrix Interaction in Cardiovascular
Regeneration, University of Eindhoven
Hierachical Vascular Networks for Tissue Engineering
The networks of blood vessels that comprise the circulatory system provide living tissue
with the required nutrients and oxygen, whilst removing waste products. Lack of
vascularisation within a large and densely populated tissue engineered construct leads
to necrotic core formation, preventing fabrication of functional tissues and organs.
Strategies for vascularization involve engineering vascularized tissue before
transplantation into the patient or by promoting vascularization in situ after
transplantation. My talk will focus on our work in this area. More specifically, I will
present: (i) A space-filling algorithm for generation of physiologically relevant three-
dimensional models of vascular structures. The vascular models are generated in a
Computer Aided Design (CAD) environment, and can be exported to any 3D printer
format. (ii) A method for production of three-dimensional and hierarchical vascular
networks in hydrogels, using sacrificial 3D printing and cellular co-cultures.
Confirmed
Athina Markaki, Reader in Tissue Engineering, University of Cambridge
15.05-15.30 Topic: employing embryonic stem cells for cardiovascular repair
Confirmed
Direct tissue engineering approaches for regenerative biology and medicine
The ability to manipulate and distribute living mammalian cells with control presents
fascinating possibilities for a plethora of applications in our healthcare. These imply
5. Sian Harding, Professor & Interim Head of the National Heart & Lung Institute,
Imperial College London
several possibilities in tissue engineering and regenerative biology/medicine, to those of
a therapeutic nature. The talk will briefly introduce leading technologies, which have
been fully validated from a physical, chemical and biological stand point for completely
demonstrating their inertness for directly handling the most intricate advanced material
known to humankind. Although several technologies will be discussed the talk will focus
of bio-electrosprays and cell electrospinning which have truly pushed back the frontiers
of tissue engineering and regenerative medicine, previously hither to unachieved by any
of its competing technologies. Successful development of these bio-protocols sees the
emergence of unique future platform strategies within both a laboratory and a clinical
environment having far-reaching consequences for our healthcare.
Confirmed
Suwan Jawasinghe, Group leader of the BioPhysics Group, University College
London
15.30-16.00 Solution Provider Presentation
For sponsorship opportunities please contact
Nick Best/Tony Couch at
Sponsorship@globalengage.co.uk
Solution Provider Presentation
For sponsorship opportunities please contact
Nick Best/Tony Couch at
Sponsorship@globalengage.co.uk
16.00-16.50 Afternoon refreshments
Poster Presentation Sessions
One to One Partnering Meetings
16.50-17.15 Panel discussion
Engineering of viable tissue constructs and the challenges of vascularization
Engineering tissue constructs on the macro scale comes with a myriad of challenges, yet
the potential of these large scale grafts is undeniable. This panel will provide a
discussion forum to explore approaches to producing viable tissues and supporting their
integration in vivo, in particular the challenges of designing and implementing a vascular
network.
Invitation to Senior Representatives X4
Topic: GMP for nanostructures and nanomaterials
Confirmed
Julian Dye, Departmental Lecturer, University of Oxford
17.15-17.40 Polyurethanes: a promising platform for tissue engineering and regenerative
medicine
The careful selection of the scaffold-forming material and fabrication technology plays a
key role in the design of three-dimensional scaffolds for tissue engineering (TE)
applications. In this context, polyurethanes (PUs) are an interesting and valuable
alternative as their high chemical versatility results in the possibility to synthesize a wide
array of polymers with finely modulated physico-chemical properties and suitability to
different fabrication technologies, either conventional or advanced. In this contribution, a
new platform of biodegradable and biocompatible PUs (either thermoplastic or
amphiphilic water-soluble PUs) will be presented and their suitability to conventional and
additive manufacturing techniques will be demonstrated. PU chemical versatility can thus
be exploited to modulate their final properties to a large extent, allowing their application
in several branches of the TE field.
Confirmed
Monica Boffito, Research Associate, Politechnico di Torino
17.40-18.05 Collective cell mechanosensing: the princess and the pea revisited
• Extracellular matrix stiffness plays a fundamental role in cell division, migration and
differentiation
• Cells mechanosense materials by deforming them, and by sensing how much
deformation occurs
• Stiffness is determined not only by material elastic modulus, but also by material
dimensions
• Cells – by acting as integrated, collective units – gather mechanical information
about their ECMs that would be impossible if acting alone
Discovery of Bio-instructive Materials
Materials that have been chosen largely on the basis of their availability and mechanical
properties dominate the range of biomaterials found in the clinic today. It would be
desirable to design our way forward from this situation to new and better biomaterials
chosen for positive interactions with surrounding cells and tissues. Unfortunately, our
understanding of the interface between most materials and biology is poor. Only in
isolated cases is there a good understanding of cell-material interactions and fewer still
where material-tissue interactions are well characterised and understood. This paucity of
information on the mechanism of biomaterial interactions within the body acts as a
roadblock to rational design. Consequently we have taken a high throughput screening
6. • This may be an important driver of many biological processes, such as integration of
biomaterials in regenerative medicine, patterning in development, wound healing,
and in cancer development/progression
Confirmed
Nick Evans, Associate Professor in Bioengineering, University of Southampton
approach to discover new bio-instructive polymers from large chemical libraries of
synthetic monomers presented as micro arrays- this approach is akin to engineering
serendipitous discovery and will be exemplified using examples that have been taken
from the lab all the way to the clinic.
Confirmed
Morgan R Alexander, The School of Pharmacy, University of Nottingham
18.05-18.30 Topic: nerve tissue regeneration
Reserved
Mathis Riehl, Reader, University of Glasgow
Topic: advancing tools for quantifying cellular forces for 3D cellular culturing
Confirmed
Hans van Oosterwick, Professor, KU Leuven
18.30 Chair’s Closing Remarks
18.30-19.30 Networking Drinks Reception
7. 08.00-08.35 Coffee & Networking meetings
08.35-08.40 Global Engage Welcome Address
Track Chair’s Opening Remarks
08.55-9.30 Keynote Presentation
Biomimetic Materials for Cartilage Engineering
• Injectable hydrogels
• Printable hydrogels
• BioLubricants
• Drug Delivery for OA Cartilage
Confirmed
Marcy Zenobi-Wong, Professor, ETH Zurich
09.30-09.55 Topic: reconstructing lung tissue utilizing a decellularized extracellular-matrix scaffold
Confirmed
Joaquin Cortiella, Professor, University of Texas Medical Branch at Galveston
09.55-10.25 Solution Provider Presentation
For sponsorship opportunities please contact
Nick Best/Tony Couch at
Sponsorship@globalengage.co.uk
10.25-11.35 Morning Refreshments
Poster Presentation Sessions
One to One Partnering Meetings
Track 1 – Hard Tissue & Cartilage Engineering Track 2 – Bioprinting & Organ Fabrication
11.35-12.00 Topic: engineering bioactive glass and ceramic for mineralised bone tissue repair
Confirmed
Paul Hatton, Professor, University of Sheffield
Topic: printing liver mimetics
Confirmed
Shirley Tang, Associate Professor, University of Waterloo
12.00-12.25 Injectable hydrogels to repair hard and soft musculoskeletal tissues
Intervertebral disc degeneration, which is strongly associated with low back pain, and
bone loss associated with degenerative disease and trauma are significant clinical
problems. Current therapies are associated with poor outcomes. This presentation will
discuss a novel injectable hydrogel system which can tailor stem cell differentiation
towards intervertebral disc cells or bone forming cells. This hydrogel can be injected via
fine bore needles into soft or hard tissues where it infiltrates cracks and fissures gelling
in situ. Promoting integration to the host tissue and stem cell migration and
differentiation, promoting regeneration of these tissues. This presentation will disc the
potential applications for this promising hydrogel and the research data derived to date.
Confirmed
Christine le Maitre, Professor of Cell Biology and Tissue Regeneration, Sheffield
Hallam University
Panel Discussion
Advances in 3D bioprinting techniques and challenges to be overcome
Bioprinting offers a revolution in the life sciences, but especially in the area of organ
fabrication and the production of large scale tissue constructs. Given the rapid
development of this technology it seems assured that it will become an integral part of
tissue engineering. This panel discussion will examine what we can expect to see next
from this exciting field, as well as the obstacles to be overcome to see widespread
adoption.
Invitation to Senior Representative X4
12.25-12.50 Topic: cranial bone grafting and advances in maxillofacial surgery
Reserved
Debby Gawlitta, Associate Professor, UMC Utrecht
12.50-13.20 Solution Provider Presentation
For sponsorship opportunities please contact
Solution Provider Presentation
For sponsorship opportunities please contact
Day Two – 13th November 2018, London, U.K.
8. Nick Best/Tony Couch at
Sponsorship@globalengage.co.uk
Nick Best/Tony Couch at
Sponsorship@globalengage.co.uk
13.20-14.20 Lunch
Poster Presentation Sessions
One to One Partnering Meetings
14.20-14.45 Activation of Novel Growth Factor Signaling Pathways for Bone Regeneration
The Hankenson laboratory studies the molecular and cellular basis for osteoblast
differentiation, and through these studies seeks to identify novel pathways that can be
utilized to enhance bone regeneration. The laboratory has most recently studied
agonists of Wnt signaling and Notch signaling and this presentation will discuss the
pathway from discovery to translation in pre-clinical animal models of bone healing.
Confirmed
Kurt Hankenson, Professor, Orthopaedic Surgery, University of Michigan
Whole-organ bioengineering: current tales of modern alchemy
Liver disease affects more than 650 million people worldwide and accounts for 4% of all
deaths. It is particularly costly in terms of human suffering, healthcare resources and
premature loss of productivity. To date, the only definitive treatment available is liver
transplantation, which substantially improves survival and the quality of life of these
patients. However, a lack of donor livers subsists, mainly due to expanding indications
and the increase of patients on waiting lists. By integrating multiple distinct enabling
technologies in one single advanced therapy medicinal product (ATMP) - a
bioengineered human liver - we aim to create and produce bioengineered human livers
for transplantation and thereby serve a large patient group with an urgent medical need.
Confirmed
Pedro Baptista, Group Leader at Aragon Health Research Institute (IIS Aragon),
Zaragoza and Assistant Professor at Carlos III University, Madrid
14.45-15.10 Topic: cell based approaches to bone tissue repair
Reserved
Aaron James, Associate Professor, John Hopkins University
Topic: producing functional heart valves from decellularized scaffolds
Confirmed
Helen Berry, University Academic Fellow, University of Leeds
15.10-15.35 Topic: joint regeneration and combinational approaches to bone and cartilage
repair
Reserved
Oran Kennedy, Royal College of Surgeons in Ireland
Topic: construction of ECM scaffolds in liver tissue fabrication
Confirmed
Shery Huang, University Lecturer in Bioengineering, University of Cambridge
15.35-16.00 Topic: utilizing marine animal tissue to develop human bone-like tissue
Reserved
Suchitra Sumitran-Holgersson, Professor of Transplantation, University of
Gothenburg
Topic: The production of kidney organoids from human pluripotent stem cells
Confirmed
Nuria Montserrat, Junior Group Leader, Institute for Bioengineering of Catalonia
(IBEC)
16.00 Conference Close